NEX-127 (Relivra®) is a first-in-class, New Chemical Entity (NCE) topical analgesic designed to deliver fast, meaningful pain relief that lasts, without the systemic burden of oral pain medications. It is built around a single proprietary prodrug molecule that combines two proven therapeutic functions in one coordinated local treatment: rapid anesthetic pain blocking and sustained anti-inflammatory analgesia. The drug is delivered in a patient-friendly thermosensitive gel that applies easily and then forms a stable local depot at skin temperature—supporting prolonged action at the site of pain, with the goal of minimizing systemic exposure and enabling opioid-sparing recovery.

​

At the molecular level, NEX-127 is engineered as a mutual prodrug linking lidocaine (a well-established fast-acting local anesthetic) with naringenin (a bioactive anti-inflammatory flavonoid) through a covalent linker, forming a single NCE rather than a conventional mixture. This design is intended to keep the system intact during handling and topical application, and then allow controlled local activation within skin tissue, releasing the two components in a sequenced, complementary way—supporting rapid onset followed by extended relief. In practical terms, NEX-127 is being developed to address one of the most persistent limitations in topical pain care: existing products typically deliver either short-lived numbness or slow-onset anti-inflammatory relief, but not both in a consistent, durable profile. NEX-127 is designed to bridge that gap with a single localized therapy that can cover the post-procedural pain window more effectively.

​

NEX-127 is positioned for high clinical and commercial relevance across large and repeatable use settings—especially post-operative and wound-related pain, including postpartum/perineal pain, orthopedic procedures, and other incisional or localized inflammatory pain scenarios. The format is intentionally practical: a simple topical gel, non-invasive, and scalable for broad deployment—while the underlying chemistry is structured as a defensible pharmaceutical asset with the characteristics strategic acquirers value, including novelty, differentiation, and lifecycle potential. As documented in the dossier, NEX-127 was designed to provide rapid onset, extended duration, deep local penetration, and meaningful opioid-sparing potential, while remaining a localized therapy with low systemic exposure—a combination that is increasingly prioritized by both regulators and commercial partners in modern pain management.